Ferdinando Squitieri

List of Publications by Year
in descending order

187 papers	13,502 citations	28190 55 h-index	24179 110 g-index
191 all docs	191 docs citations	191 times ranked	12913 citing authors

#	Article	IF	Citations
1	Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism. Science, 2003, 299, 256-259.	6.0	2,467
2	The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genetics, 1993, 4, 398-403.	9.4	1,002
3	A Worldwide Study of the Huntington's Disease Mutation: The Sensitivity and Specificity of Measuring CAG Repeats. New England Journal of Medicine, 1994, 330, 1401-1406.	13.9	563
4	DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurological Sciences, 2003, 24, 159-160.	0.9	363
5	Loss of normal huntingtin function: new developments in Huntington's disease research. Trends in Neurosciences, 2001, 24, 182-188.	4.2	341
6	Mutations in a Gene Encoding a Novel Protein Containing a Phosphotyrosine-Binding Domain Cause Type 2 Cerebral Cavernous Malformations. American Journal of Human Genetics, 2003, 73, 1459-1464.	2.6	319
7	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-1562.	1.5	312
8	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology, 2012, 78, 690-695.	1.5	303
9	Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature, 2017, 545, 108-111.	13.7	288
10	Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nature Genetics, 1993, 5, 174-179.	9.4	248
11	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
12	Impaired PGC-1Î± function in muscle in Huntington's disease. Human Molecular Genetics, 2009, 18, 3048-3065.	1.4	215
13	Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. Journal of Nuclear Medicine, 2006, 47, 215-22.	2.8	201
14	Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Human Molecular Genetics, 1993, 2, 1535-1540.	1.4	189
15	DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Human Molecular Genetics, 1994, 3, 2103-2114.	1.4	178
16	Recommendations for the predictive genetic test in Huntington's disease. Clinical Genetics, 2013, 83, 221-231.	1.0	175
17	Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 2003, 126, 946-955.	3.7	173
18	DJ-1 Transcriptionally Up-regulates the Human Tyrosine Hydroxylase by Inhibiting the Sumoylation of Pyrimidine Tract-binding Protein-associated Splicing Factor. Journal of Biological Chemistry, 2006, 281, 20940-20948.	1.6	162

#	Article	IF	Citations
19	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2011, 10, 1049-1057.	4.9	157
20	Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 574-577.	1.1	142
21	Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPAgene in Italian families. Neurological Sciences, 2004, 25, 130-137.	0.9	131
22	Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. American Journal of Human Genetics, 2019, 104, 1116-1126.	2.6	130
23	The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Human Molecular Genetics, 2003, 12, 2807-2816.	1.4	128
24	Suicide risk in Huntington's disease.. Journal of Medical Genetics, 1993, 30, 293-295.	1.5	118
25	Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Lancet Neurology, The, 2018, 17, 986-993.	4.9	115
26	The Relationship Between CAG Repeat Length and Age of Onset Differs for Huntington's Disease Patients with Juvenile Onset or Adult Onset. Annals of Human Genetics, 2007, 71, 295-301.	0.3	110
27	Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Human Mutation, 2006, 27, 118-118.	1.1	98
28	International Guidelines for the Treatment of Huntington's Disease. Frontiers in Neurology, 2019, 10, 710.	1.1	98
29	The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism and Related Disorders, 2013, 19, 192-197.	1.1	96
30	Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mechanisms of Ageing and Development, 2006, 127, 217-220.	2.2	85
31	FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Human Molecular Genetics, 2014, 23, 2251-2265.	1.4	84
32	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	4.9	82
33	Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death and Differentiation, 2006, 13, 2068-2078.	5.0	81
34	Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neuroscience and Biobehavioral Reviews, 2013, 37, 480-490.	2.9	81
35	Deletions in CCM2 Are a Common Cause of Cerebral Cavernous Malformations. American Journal of Human Genetics, 2007, 80, 69-75.	2.6	80
36	Managing juvenile Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 267-276.	1.2	78

#	Article	IF	Citations
37	Aberrant A 2A receptor function in peripheral blood cells in Huntington's disease. FASEB Journal, 2003, 17, 1-16.	0.2	75
38	Whole body cholesterol metabolism is impaired in Huntington's disease. Neuroscience Letters, 2011, 494, 245-249.	1.0	75
39	Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington disease. Human Molecular Genetics, 1995, 4, 189-195.	1.4	74
40	Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Annals of Neurology, 2002, 51, 253-256.	2.8	74
41	Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy, 2015, 23, 1759-1771.	3.7	73
42	Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clinical Genetics, 2001, 58, 50-56.	1.0	72
43	Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study. BMC Medical Genetics, 2006, 7, 71.	2.1	72
44	Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease. CNS Neuroscience and Therapeutics, 2009, 15, 1-11.	1.9	69
45	Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability. Behavioural Neurology, 2017, 2017, 1-10.	1.1	67
46	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	1.6	64
47	Multimodal MRI Analysis of the Corpus Callosum Reveals White Matter Differences in Presymptomatic and Early Huntington's Disease. Cerebral Cortex, 2012, 22, 2858-2866.	1.6	64
48	Phosphorylation of huntingtin at residue T3 is decreased in Huntingtonâ€™s disease and modulates mutant huntingtin protein conformation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10809-E10818.	3.3	63
49	Juvenile Huntington's disease: Does a dosage-effect pathogenic mechanism differ from the classical adult disease?. Mechanisms of Ageing and Development, 2006, 127, 208-212.	2.2	62
50	Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Journal of Cellular and Molecular Medicine, 2015, 19, 2540-2548.	1.6	62
51	Onset symptoms in 510 patients with Huntington's disease.. Journal of Medical Genetics, 1993, 30, 289-292.	1.5	60
52	Novel parkin mutations detected in patients with early-onset Parkinson's disease. Movement Disorders, 2005, 20, 424-431.	2.2	60
53	18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1030-1036.	3.3	60
54	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012, 90, 434-444.	2.6	60

#	Article	IF	Citations
55	Seeking huntington disease biomarkers by multimodal, crossâ€sectional basal ganglia imaging. Human Brain Mapping, 2013, 34, 1625-1635.	1.9	60
56	The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 346-357.	1.1	60
57	Molecular analysis of late onset Huntington's disease.. Journal of Medical Genetics, 1993, 30, 991-995.	1.5	57
58	Tractography of the Corpus Callosum in Huntingtonâ€™s Disease. PLoS ONE, 2013, 8, e73280.	1.1	56
59	Abnormal morphology of peripheral cell tissues from patients with Huntington disease. Journal of Neural Transmission, 2010, 117, 77-83.	1.4	55
60	A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease. JAMA Neurology, 2013, 70, 25.	4.5	53
61	The prolonged cortical silent period in patients with Huntington's disease. Clinical Neurophysiology, 2001, 112, 1470-1474.	0.7	52
62	Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1113-1120.	3.3	52
63	Major Superficial White Matter Abnormalities in Huntington's Disease. Frontiers in Neuroscience, 2016, 10, 197.	1.4	51
64	The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. Parkinsonism and Related Disorders, 2018, 49, 42-47.	1.1	46
65	Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?. Journal of the Neurological Sciences, 2009, 277, 143-146.	0.3	44
66	Onset and pre-onset studies to define the Huntingtonâ€™s disease natural history. Brain Research Bulletin, 2001, 56, 233-238.	1.4	43
67	Huntington's disease: How intermediate are intermediate repeat lengths?. Movement Disorders, 2012, 27, 1714-1717.	2.2	42
68	MRI measures of corpus callosum iron and myelin in early Huntington's disease. Human Brain Mapping, 2014, 35, 3143-3151.	1.9	42
69	The gender effect in juvenile Huntington disease patients of Italian origin. American Journal of Medical Genetics Part A, 2004, 125B, 92-98.	2.4	41
70	Deep White Matter in Huntington's Disease. PLoS ONE, 2014, 9, e109676.	1.1	41
71	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. Neurological Sciences, 2002, 23, s59-s60.	0.9	40
72	Factor analysis of behavioural symptoms in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 411-412.	0.9	38

#	Article	IF	Citations
73	The role of iron in gray matter degeneration in Huntington's disease: A magnetic resonance imaging study. Human Brain Mapping, 2015, 36, 50-66.	1.9	38
74	Epidemiology of Huntington disease: first postâ€‹<scp>HTT</scp> gene analysis of prevalence in Italy. Clinical Genetics, 2016, 89, 367-370.	1.0	38
75	The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neuroscience Letters, 2006, 393, 27-30.	1.0	35
76	Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mechanisms of Ageing and Development, 2006, 127, 213-216.	2.2	35
77	Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases.. Journal of Medical Genetics, 1993, 30, 987-990.	1.5	34
78	What is the impact of education on Huntington's disease?. Movement Disorders, 2011, 26, 1489-1495.	2.2	34
79	Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatric Disease and Treatment, 2009, 5, 1-4.	1.0	34
80	Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. Neurogenetics, 2008, 9, 25-31.	0.7	33
81	Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders, 2015, 30, 1426-1429.	2.2	33
82	The Corticospinal Tract in Huntington's Disease. Cerebral Cortex, 2015, 25, 2670-2682.	1.6	33
83	Polymorphism analysis of the huntingtin gene in Italian families affected with Huntington disease. Human Molecular Genetics, 1994, 3, 1129-1132.	1.4	32
84	Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 691-695.	1.1	32
85	Truncated Peroxisome Proliferator-Activated Receptor-Î³ Coactivator 1Î± Splice Variant Is Severely Altered in Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2011, 8, 496-503.	0.8	32
86	Polyglutamine expansion affects huntingtin conformation in multiple Huntingtonâ€™s disease models. Scientific Reports, 2017, 7, 5070.	1.6	32
87	Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine, 2020, 22, 2108-2113.	1.1	32
88	Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 139B, 101-105.	1.1	31
89	Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. Journal of Neurochemistry, 2006, 98, 1090-1099.	2.1	31
90	Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?. Frontiers in Neurology, 2019, 10, 453.	1.1	31

#	Article	IF	Citations
91	ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations. Neuroscience, 2008, 155, 345-349.	1.1	30
92	Exploring emotion regulation and emotion recognition in people with presymptomatic Huntington's disease: The role of emotional awareness. Neuropsychologia, 2018, 112, 1-9.	0.7	29
93	Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases. Cell Death and Disease, 2020, 11, 861.	2.7	29
94	DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. Annals of Neurology, 2019, 85, 296-301.	2.8	28
95	A Double-Blind Cross-over Trial of Amantadine Hydrochloride in Friedreich's Ataxia. Canadian Journal of Neurological Sciences, 1993, 20, 52-55.	0.3	27
96	Analysis of (CAG)n size heterogeneity in somatic and sperm cell DNA from intermediate and expanded Huntington disease gene carriers. , 1997, 10, 458-464.		27
97	Presymptomatic tests in Huntington's disease and dominant ataxias. Neurological Sciences, 2001, 22, 55-56.	0.9	27
98	Novel T719P AÎ²PP Mutation Unbalances the Relative Proportion of Amyloid-Î² Peptides. Journal of Alzheimer's Disease, 2009, 18, 295-303.	1.2	27
99	Population stratification may bias analysis of PGC-1Î± as a modifier of age at Huntington disease motor onset. Human Genetics, 2012, 131, 1833-1840.	1.8	26
100	Changes of peripheral TGF-Î²1 depend on monocytes-derived macrophages in Huntington disease. Molecular Brain, 2013, 6, 55.	1.3	26
101	CAG mutation effect on rate of progression in Huntington's disease. Neurological Sciences, 2002, 23, s107-s108.	0.9	24
102	DNA instability in replicating Huntington's disease lymphoblasts. BMC Medical Genetics, 2009, 10, 11.	2.1	24
103	Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG₃₃ repeat length in the Huntington's disease gene. Movement Disorders, 2011, 26, 925-927.	2.2	24
104	Polyglutamine tracts regulate autophagy. Autophagy, 2017, 13, 1613-1614.	4.3	23
105	A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. American Journal of Human Genetics, 2019, 105, 1112-1125.	2.6	23
106	Discriminant Analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 399-402.	0.9	22
107	Optical coherence tomography (OCT) study in Argentinean Huntingtonâ€™s disease patients. International Journal of Neuroscience, 2018, 128, 1157-1162.	0.8	22
108	Four novel SPG3A/atlastin mutations identified in autosomal dominant hereditary spastic paraplegia kindreds with intraâ€familial variability in age of onset and complex phenotype. Clinical Genetics, 2009, 75, 485-489.	1.0	21

#	Article	IF	Citations
109	Seeking Brain Biomarkers for Preventive Therapy in Huntington Disease. CNS Neuroscience and Therapeutics, 2011, 17, 368-386.	1.9	21
110	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	1.0	20
111	Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?. Amino Acids, 2017, 49, 1147-1157.	1.2	20
112	Highly disabling cerebellar presentation in Huntington disease. European Journal of Neurology, 2003, 10, 443-444.	1.7	19
113	Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatric Disease and Treatment, 2008, , 1.	1.0	19
114	The personal experience of parenting a child with Juvenile Huntingtonâ€™s Disease: perceptions across Europe. European Journal of Human Genetics, 2013, 21, 1042-1048.	1.4	19
115	One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology, 2013, 80, 1086-1094.	1.5	19
116	Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease. PLoS ONE, 2014, 9, e89745.	1.1	19
117	Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease. CNS Neuroscience and Therapeutics, 2016, 22, 686-690.	1.9	19
118	Restingâ€state connectivity and modulated somatomotor and defaultâ€mode networks in Huntington disease. CNS Neuroscience and Therapeutics, 2017, 23, 488-497.	1.9	19
119	Clinical and genetic characteristics of late-onset Huntington's disease. Parkinsonism and Related Disorders, 2019, 61, 101-105.	1.1	17
120	Mutation of thePRNP gene at codon 211 in familial Creutzfeldt-Jakob disease. American Journal of Medical Genetics Part A, 2001, 103, 133-137.	2.4	16
121	PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. Journal of Cellular Physiology, 2011, 226, 948-961.	2.0	16
122	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. Movement Disorders, 2019, 34, 584-585.	2.2	16
123	Emotional processing in RRMS patients: Dissociation between behavioural and neurophysiological response. Multiple Sclerosis and Related Disorders, 2019, 27, 344-349.	0.9	16
124	The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction. European Journal of Neurology, 2006, 13, 408-415.	1.7	15
125	Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. Journal of Neural Transmission, 2011, 118, 1599-1607.	1.4	15
126	Validation of the first quality-of-life measurement for patients with Huntingtonâ€™s disease. International Clinical Psychopharmacology, 2012, 27, 208-214.	0.9	15

#	Article	IF	Citations
127	Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Design, Development and Therapy, 2015, 9, 5827.	2.0	15
128	Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol. Multiple Sclerosis Journal, 2018, 24, 1328-1336.	1.4	15
129	Task-switching abilities in pre-manifest Huntington's disease subjects. Parkinsonism and Related Disorders, 2019, 60, 111-117.	1.1	15
130	Modeling Manifest Huntingtonâ€™s Disease Prevalence Using Diagnosed Incidence and Survival Time. Neuroepidemiology, 2021, 55, 361-368.	1.1	15
131	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. Journal of Huntington's Disease, 2018, 7, 209-222.	0.9	14
132	Key role of nuclear medicine in seeking biomarkers of Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1124-1127.	3.3	13
133	'Fifty shades of grey' in the Huntington disease gene. Nature Reviews Neurology, 2013, 9, 421-422.	4.9	13
134	Psychiatric onset and late chorea in a patient with 41 CAG repeats in the TATA-binding protein gene. Parkinsonism and Related Disorders, 2014, 20, 678-679.	1.1	13
135	Utility of the Parkinsonâ€™s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntingtonâ€™s disease. Journal of Neurology, 2020, 267, 1527-1535.	1.8	13
136	Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease. NeuroReport, 2007, 18, 1997-2000.	0.6	12
137	Early enteric neuron dysfunction in mouse and human HuntingtonÂdisease. Parkinsonism and Related Disorders, 2017, 34, 73-74.	1.1	12
138	CM-Pf deep brain stimulation and the long term management of motor and psychiatric symptoms in a case of Tourette syndrome. Journal of Clinical Neuroscience, 2019, 62, 269-272.	0.8	12
139	Mitochondrial Respiration Changes in R6/2 Huntingtonâ€™s Disease Model Mice during Aging in a Brain Region Specific Manner. International Journal of Molecular Sciences, 2020, 21, 5412.	1.8	12
140	Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective crossâ€sectional study. Brain and Behavior, 2021, 11, e02151.	1.0	12
141	Cavernous angiomas of the nervous system in Italy: clinical and genetic study. Neurological Sciences, 2000, 21, 129-134.	0.9	11
142	Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. Clinical Genetics, 2003, 64, 524-525.	1.0	11
143	Juvenile Huntington disease in Argentina. Arquivos De Neuro-Psiquiatria, 2016, 74, 50-54.	0.3	11
144	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntingtonâ€™s disease motor onset. Neurogenetics, 2013, 14, 173-179.	0.7	10

#	Article	IF	Citations
145	Antidopaminergic Medication is Associated with More Rapidly Progressive Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 131-140.	0.9	10
146	New Huntington disease mutation arising from a paternal CAG34allele showing somatic length variation in serially passaged lymphoblasts. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 127-130.	1.1	9
147	Neuroprotective effects of riluzole in Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 221-222.	3.3	9
148	Current Pharmacological Management in Juvenile Huntingtonâ€™s Disease. PLOS Currents, 2012, 4, RRN1304.	1.4	9
149	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1411-1413.	0.9	8
150	Further evidence of reliability and validity of the Huntingtonâ€™s disease quality of life battery for carers: Italian and French translations. Quality of Life Research, 2013, 22, 1093-1098.	1.5	8
151	Generation of induced pluripotent stem cell line CSSi008-A (4698) from a patient affected by advanced stage of Dentato-Rubral-Pallidoluysian atrophy (DRPLA). Stem Cell Research, 2019, 40, 101551.	0.3	8
152	Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. Genetics in Medicine, 2020, 22, 1903-1908.	1.1	8
153	A Novel Triplet-Primed PCR Assay to Detect the Full Range of Trinucleotide CAG Repeats in the Huntingtin Gene (HTT). International Journal of Molecular Sciences, 2021, 22, 1689.	1.8	8
154	Generation of induced pluripotent stem cell line, CSSi004-A (2962), from a patient diagnosed with Huntington's disease at the presymptomatic stage. Stem Cell Research, 2018, 28, 145-148.	0.3	7
155	Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment. Journal of Personalized Medicine, 2022, 12, 36.	1.1	7
156	Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2019, 8, 181-193.	0.9	6
157	Effects of stimulus-related variables on mental states recognition in Huntingtonâ€™s disease. International Journal of Neuroscience, 2019, 129, 563-572.	0.8	6
158	Abnormal visual scanning and impaired mental state recognition in pre-manifest Huntington disease. Experimental Brain Research, 2021, 239, 141-150.	0.7	6
159	Italian Huntington disease patients-data and tissue bank. Neurological Sciences, 2003, 24, 215-216.	0.9	5
160	Molecular medicine: predicting and preventing Huntingtonâ€™s disease. Neurological Sciences, 2008, 29, 205-207.	0.9	5
161	Generation of induced pluripotent stem cell line, CSSi002-A (2851), from a patient with juvenile Huntington Disease. Stem Cell Research, 2018, 27, 86-89.	0.3	5
162	Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinsonâ€™s and Huntingtonâ€™s diseases. Neurological Sciences, 2021, 42, 4997-5006.	0.9	5

#	Article	IF	Citations
163	Known Drugs Identified by Structure-Based Virtual Screening Are Able to Bind Sigma-1 Receptor and Increase Growth of Huntington Disease Patient-Derived Cells. International Journal of Molecular Sciences, 2021, 22, 1293.	1.8	5
164	Sleep Quality and Related Clinical Manifestations in Huntington Disease. Journal of Personalized Medicine, 2022, 12, 864.	1.1	5
165	Update on genetics of Huntington's disease: availability of direct and accurate predictive test. Italian Journal of Neurological Sciences, 1996, 17, 185-187.	0.1	4
166	Perceptions about Research Participation among Individuals at Risk and Individuals with Premanifest Huntingtonâ€™s Disease: A Survey Conducted by the European Huntington Association. Journal of Personalized Medicine, 2021, 11, 815.	1.1	4
167	Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task. Neural Regeneration Research, 2020, 15, 1518.	1.6	4
168	Assessment Of The Huntington Quality Of Life Instrument (H-QOL-I) Cross-Cultural Validity. Value in Health, 2014, 17, A567.	0.1	3
169	Safer Attitude to Risky Decision-Making in Premanifest Huntingtonâ€™s Disease Subjects. Frontiers in Psychology, 2019, 10, 846.	1.1	3
170	Incidence and prevalence of Huntington disease (HD) in the Sultanate of Oman: the first Middle East post-HTT service-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1359-1360.	0.9	3
171	Validity of the Italian multiple sclerosis neuropsychological screening questionnaire. Neurological Sciences, 2021, 42, 4583-4589.	0.9	2
172	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. BMJ Case Reports, 2009, 2009, bcr0820080711-bcr0820080711.	0.2	2
173	Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2021, 10, 1-10.	0.9	2
174	Generation of the induced pluripotent stem cell line CSSi006-A (3681) from a patient affected by advanced-stage Juvenile Onset Huntington's Disease. Stem Cell Research, 2018, 29, 174-178.	0.3	1
175	â€œSpazio Huntingtonâ€: Tracing the Early Motor, Cognitive and Behavioral Profiles of Kids with Proven Pediatric Huntington Disease and Expanded Mutations > 80 CAG Repeats. Journal of Personalized Medicine, 2022, 12, 120.	1.1	1
176	18F-fluorodeoxyglucose-PET as a biomarker in Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 489-491.	1.2	0
177	Assessment Of The Huntington Clinical Self-Reported Instrument (H-CSRI) Cross-Cultural Validity. Value in Health, 2014, 17, A567.	0.1	0
178	F13â€…Assessment of the performance of a modified motor scale as applied to juvenile onset huntingtonâ€™s disease. , 2018, , .		0
179	H01â€…Upcoming international guidelines in huntingtonâ€™s disease. , 2018, , .		0
180	B18â€…Human induced neural stem cells as model to study the neural development in huntingtonâ€™s disease. , 2018, , .		0

#	Article	IF	Citations
181	F34â€…Game of dice task performance in premanifest huntingtonâ€™s disease subjects. , 2018, , .		0
182	Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology, 2017, 88, 334-334.	1.5	0
183	F02â€…A cluster of HD in italy with several subjects carrying cag expansion homozygousity in different generations and genetic risk over 50%. , 2018, , .		0
184	F75â€…A huntingtonâ€™s disease (HD) database at lirh foundation (LIRH-rome site): enroll-hd study as a starting point. , 2018, , .		0
185	F33â€…Task-switching abilities in pre-manifest huntingtonâ€™s disease subjects. , 2018, , .		0
186	A22â€…Sorcin rescues ca (II) dysregulation and endoplasmic reticulum stress in huntingtonâ€™s disease. , 2018, , .		0
187	Genetic linkage analysis and presymptomatic testing in Huntington's disease. First report in Italy. Acta Neurologica, 1992, 14, 524-9.	0.1	0